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Abstract
Extracellular deposition of amyloid beta peptide (A) has been implicated as a critical step in the pathogenesis of Alzheimer’s disease (AD).
n Down syndrome (DS), Alzheimer’s disease is assumed to be caused by the triplication and overexpression of the gene for amyloid precursor
rotein (APP), located on chromosome 21. Plasma concentrations of A1–40 and A1–42 were determined in a population based study of 506
persons with DS, who were screened annually for dementia. We used Cox proportional hazards models to determine the risk of dementia.
Demented persons with DS have a significantly higher plasma A1–40 concentration than the nondemented (p  0.05). Those with the highest
concentrations of A1–40 and A1–42 have a higher risk to develop dementia. The risk to develop dementia during follow-up (mean 4.7 years)
increased to 2.56 (95% confidence interval, 1.39–4.71) for A1–42 and 2.16 (95% confidence interval, 1.14–4.10) for A1–40. High plasma
concentration of plasma A1–40 and A1–42 are determinants of the risk of dementia in persons with DS.
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a
m1. Introduction
Increasing evidence suggests that a key event in the patho-
genesis of Alzheimer’s disease (AD) is the altered production,
aggregation, and deposition of amyloid beta peptide (A), a
roteolytic fragment derived from amyloid precursor protein
APP). APP is cleaved by a combination of  and  secretase
nzyme activity to produce the longer more toxic 42 amino
cid long peptide (A1–42) or the shorter, more soluble
0-amino acid peptide (A1–40) (Selkoe, 1994). The in-
reased risk of AD in people with Down syndrome (DS) is
* Corresponding author at: Genetic Epidemiology Unit, Department of
Epidemiology, Erasmus MC University Medical Center, Rotterdam, PO
Box 2040, 3000 CA, Rotterdam, The Netherlands. Tel: 31 10 7043391;
fax: 31 10 7044232.OE-mail address: a.coppus@erasmusmc.nl (A.M.W. Coppus).
0197-4580 © 2012 Elsevier Inc.
10.1016/j.neurobiolaging.2011.08.007
Open access under the Elsevier OA license.ell known (Coppus et al., 2006; Schupf and Sergievsky,
002). In DS, AD is assumed to be caused by the triplication
nd overexpression of the gene for APP, located on chro-
osome 21 and leading to the accumulation of cerebral
-amyloid (Wisniewski et al., 1985). Increased levels of
A1–42 have been found in familial forms of early onset
AD. This relationship is seen both in families with muta-
tions in the gene for APP and in the presenilin genes
(Kosaka et al., 1997). Studies of the relation of plasma
levels of A1–42 and A1–40 to risk of late onset AD in
the general population have been inconsistent. High plasma
levels of A1–42 and A1–40 were associated with the
increased risk of development of AD in the Northern Man-
hattan Study of Aging and Dementia (Mayeux et al., 2003)
and high plasma levels of A40 in the Rotterdam study (vanijen et al., 2006), but others suggested that A40 is lower
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2008). Further, a low A1–42:A1–40 ratio has been as-
ociated with an increased Alzheimer risk (Graff-Radford et
l., 2007; Lambert et al., 2009) which may imply a prefer-
ntial increase of plasma A1–40 over A1–42 before the
disease, or a preferential decrease of A1–42 over A1–40.
he most recent and largest population-based study, the
rospective 3-city study found a decrease of A1–42:
A1–40 ratio to be most predictive (Lambert et al., 2009).
When testing the association of A1–42 and A1–40 in-
dividually, A1–42 was decreased in persons who devel-
ped dementia later in life, but this relationship was not
ignificant. A1–40, on the other hand, was significantly
increased in patients who developed dementia.
In DS, plasma levels of A1–42 and A1–40 are con-
istently higher than in age-matched controls at all ages
egardless of dementia status (Cavani et al., 2000; Mehta et
l., 2003, 2007; Schupf et al., 2001; Tokuda et al., 1997).
evels of A1–42 and/or A1–40 seem to increase with
ge and are associated with the presence of dementia in
ome studies (Mehta et al., 2007; Schupf et al., 2001, 2007)
ut not in all (Jones et al., 2009; Matsuoka et al., 2009). In
S patients, plasma levels changed after the onset of de-
entia but findings are not consistent. In a longitudinal
tudy (Prasher et al., 2010), plasma A1–40 decreased over
time after the onset of dementia and plasma A1–42 in-
creased with increasing duration of dementia. Another lon-
gitudinal study (Schupf et al., 2010) showed that plasma
A1–42 levels decreased and A1–40 levels increased
fter the onset of dementia. Differences in the timing of the
 measurements with respect to the dementia diagnosis
ould be responsible for the differences in the results be-
ween these longitudinal studies.
The aim of this study was to evaluate A plasma levels
s possible biomarkers of amyloid accumulation in the brain
n people with DS. We investigated this in the largest
ongitudinal study of elderly persons with DS (Coppus et
l., 2006).
. Methods
.1. Study population
We conducted a study of 506 persons with DS, aged 45
ears and older, who were enrolled from 1 December 1999
o 1 December 2003 in a community-based study on DS and
ging in the Netherlands. Informed consent procedures and
ecruiting of subjects have been described in detail else-
here (Coppus et al., 2006). At the time of study entry, each
erson received a complete assessment including interviews
ith relatives, caregivers, and the general practitioner. The
edical records were reviewed. All persons underwent a
eneral physical and neurological examination. At baseline,
asting venous blood samples were taken in the morning.
lasma concentration of A1–40 and A1–42 was mea-sured in 405 (80%) persons who consented to give (suffi- ccient) blood. All participants were assessed once yearly up
to the reference date of 1 January 2007 or date of death. For
this study the diagnosis of DS was re-evaluated based on
clinical characteristics according to the criteria described by
Roizen and Patterson (2003). In 236 cases (58%) the clinical
diagnosis was confirmed by available cytogenetic charac-
terization.
2.2. Clinical assessments
Premorbid severity of intellectual disability (ID) was
classified into 2 groups, using the International Classifica-
tion of Diseases (ICD)-10: mild/moderate (IQ 35–70) and
severe/profound (IQ  35). Apolipoprotein E (APOE) ge-
notype was determined as described in a previous study
(Coppus et al., 2008). Participants were classified according
to the presence or absence of an APOE4 allele. Body mass
index (BMI) was computed as weight in kilograms divided
by height in square meters.
All persons were assessed for AD using the ICD-10 (World
Health Organization, 1992) criteria and according to the guide-
lines produced by an international consensus panel established
under the auspices of the Ageing Special Interest Group of the
International Association for the Scientific Study of Intellectual
Disabilities (IASSID) (Aylward et al., 1997). The diagnosis of
dementia was supported using the Dementia Questionnaire for
persons with an intellectual disability (DMR) (Evenhuis, 1992,
1996) and the Social Competence Rating Scale for persons
with an intellectual disability (SRZ) (Krayer and Bildt, 2004).
Persons who were not demented were screened annually.
Those who fulfilled the criteria for AD, at baseline or during
follow-up, were followed more intensively at 6-month inter-
vals. These patients also received a clinical work-up, to ex-
clude other physical and psychiatric factors as possible causes
of deterioration.
For the prevalent cases of dementia, age at entry was
used to estimate the age at diagnosis of dementia. Age at
diagnosis of patients with incident dementia was determined
as the midpoint between the age of the person last known to
be at risk for dementia and age at diagnosis.
2.3. Measurements
Fasting blood samples were obtained following standard-
ized protocols. Plasma was prepared by a 20-minute centrifu-
gation step at 2650g and stored at 80 °C and only thawed
immediately before A quantification. Plasma A concentra-
ions were measured using a bead-based immunoassay using
MAP technology (Innogenetics) on a Luminex200 platform
sing the manufacturer’s protocols. In this study, we used data
btained for full-length A peptides, i.e., A1–40 and A1–
2, and their ratio, for analysis.
.4. Statistics
In preliminary analyses we used 2 to analyze categorical
ariables and Student t test and analysis of variance to
ompare characteristics of participants and A peptide lev-
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1990 A.M.W. Coppus et al. / Neurobiology of Aging 33 (2012) 1988–1994els by dementia status. Because not all of the data sets
showed normal distribution, we used the Mann-Whitney U
test and Kruskal-Wallis to compare levels of A1–40,
1–42, and their ratio by dementia status. To study the
association between baseline levels of A1–42 and
A1–40 and other characteristics, we used Spearman rank
correlation analysis.
Among those who were not demented at baseline, we
used Kaplan-Meier life table methods and Cox proportional
hazards models to estimate cumulative incidence and the
hazard rate (HR) of dementia by tertile of A. The lowest
ertiles were used as reference categories, first in models
djusted for age and sex (model 1) and then in models
hich adjusted for age, sex, BMI, level of ID, and the
resence of at least 1 APOE4 allele (model 2).
The median value of A1–40 (324 pg/mL) and the
median value of A1–42 (51 pg/mL) were used as a cutoff
point defining high level A versus low level. We used
aplan-Meier life table methods and Cox proportional haz-
rds models to estimate cumulative incidence and the HR of
ementia comparing the highest levels with a combination
f the lowest levels of A1–40 and A1–42. The time to
vent variable was follow-up time until reference date,
eath, or the incidence of dementia.
. Results
.1. Characteristics
At baseline assessment, there were 62 (15.3%) persons
ith clinically diagnosed AD. Over the follow-up period
Table 1
Characteristics by final diagnosis
Characteristics All
n (%) 405 (100)
Age mean (SD) a 51.6 (5.1)
ender, women, n (%) 154 (38)
POE 4 allele, n (%) 111 (27.6)
1–40, mean (SD) c,d 337.4 (104.9)
1–42, mean (SD) 51.4 (15.2)
1–42:A1–40, mean (SD) 0.16 (0.06)
ey: AD at baseline, prevalent dementia; AD at follow-up, incident deme
a p  0.001 in comparison with nondemented persons.
b p  0.001 in comparison with nondemented persons.
c p  0.04 in comparison with nondemented persons.
d p  0.01 in comparison with nondemented persons.
Table 2
The relation between the presence of an APOE 4 allele and the concentra
APOE 4 allele Demented n
 234
 56
 90
 21
omparing the 4 groups: mean concentration (95% confidence interval [C
ey: A, amyloid beta peptide; APOE, apolipoprotein E.ith a mean of 4.7 years (minimum 0.1 to maximum 7.6
ears), 79 (23.2%) persons out of 343 without dementia
eveloped AD, and 80 (20%) persons died. The mean time
rom baseline to dementia onset was 2.19 ( 1.4) years.
ersons who had AD or developed AD were more likely to
e older (Table 1). The frequency of the APOE4 allele was
reater in those with dementia than those without but this
ifference was not significant (Table 1). Comparing the
incident) demented and nondemented, with and without an
POE4 allele, there was a significant difference in
1–40 concentration (p  0.05) (Table 2).
Plasma A1–40 and A1–42 levels were correlated (r 
.35; p  0.001). Levels of A1–40 but not A1–42, were
significantly related to age at diagnosis of dementia (r 0.22;
 0.009; and r  0.06; p  0.46, respectively).
At baseline, 8 (13%) of the 62 prevalent demented persons
received a diagnosis, Reisberg stage 7, end-stage of dementia
(Reisberg et al., 1982). There was no significant difference in
A concentrations that reflects the severity of dementia.
3.2. A plasma levels and the risk of dementia
Plasma A1–42 levels were highest among those who
eveloped AD during follow-up (54.0  14.7 pg/mL) and
owest among those with dementia at baseline (50.0 17.5
g/mL). However, these differences were not significant
Table 1). The initial A1–40 levels were significantly
higher in persons with AD, prevalent as well as incident
cases, than in persons who remained nondemented during
follow-up. There was no significant difference in plasma
at
line
AD at follow-up Nondemented
2 (15.3) 79 (19.5) 264 (65.2)
0 (5.9)a 53.3 (5.4)b 50.6 (4.4)
6 (41.9) 33 (41.8) 95 (36)
2 (36.1) 21 (27.3) 68 (25.8)
3 (103.5)c 362.6 (113.5)d 326.4 (101.3)
0 (17.5) 54.0 (14.7) 51.0 (14.8)
5 (0.06) 0.16 (0.06) 0.16 (0.05)
A in persons with and without incident dementia
A40 A42
329.6 (95% CI, 316.5–342.7) 50.5 (95% CI, 48.5–52.5)
360.2 (95% CI, 329.1–391.2) 53.6 (95% CI, 49.6–57.6)
335.4 (95% CI, 313.5–357.2) 51.2 (95% CI, 48.0–54.4)
372.1 (95% CI, 320.0–424.2) 57.3 (95% CI, 51.3–63.2)
0: df 3; Kruskal-Wallis; p  0.05; A42: df 3; Kruskal-Wallis; p  0.15.AD
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ented persons in this study population.
Table 3 shows that those in the highest tertile of plasma
1–42 were at significantly higher risk of developing AD
during follow-up: HR, 1.78 (95% confidence interval [CI],
1.03–3.08). When including age at the start, sex, BMI, level
of intellectual disability, and APOE4 in the Cox model, the
risk of incident AD was 2.56-fold increased (95% CI, 1.39–
follow-u
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Fig. 1. Risk of Alzheimer’s disease during follow-up by a combination of
ge, sex, level of intellectual disability, presence of APOE 4 allele, and b
follows: (1) plasma concentration A1–40  324 pg/mL; plasma concen
lasma concentration A1–42  51 pg/mL; (3) plasma concentration A
able 3
ssociation between plasma A and risk of dementia
A42 A40
Model 1 Model 2 Model
owest tertile Ref. Ref. Ref.
iddle tertile 1.18 (0.67–2.06) 1.49 (0.79–2.84) 2.00 (1
ighest tertile 1.78 (1.03–3.08)a 2.56 (1.39–4.71)a 1.75 (0
ge 1.11 (1.07–1.16)a 1.09 (1.05–1.14)a 1.11 (1
Sex 1.18 (0.75–1.85) 1.02 (0.60–1.75) 1.24 (0
BMI 1.00 (0.95–1.06)
Level ID 1.22 (0.72–2.08)
APOE 1.18 (0.69–2.03)
Hazard ratios (95% confidence interval) for Alzheimer’s disease.
Model 1 was adjusted for age and sex.
Model 2 was adjusted for age, sex, body mass index (BMI), level of inte
Key: A, amyloid beta peptide; APOE, apolipoprotein E; Ref., reference
a p  0.05.concentration A1–40  324 pg/mL; plasma concentration A1–42  51 pg/m4.71). As can be seen in Table 3, there was also an associ-
ation between plasma A40 level and the risk of developing
D. The middle and the highest tertile showed a signifi-
antly increased risk of incident dementia compared with
he lowest tertile (HR, 2.05; 95% CI, 1.05–4.02; and HR,
.16; 95% CI, 1.14–4.09, respectively).
Because A1–40 and A1–42 were significantly corre-
lated, we evaluated to what extent the relationship to dementia
rs)
6,005,004,00
4,00
3,00
2,00
1,00
concentrations amyloid beta peptide (A)1–40 and A1–42, adjusted for
ss index. Plasma concentrations of A1–40 and A1–42 are identified as
A1–42  51 pg/mL; (2) plasma concentration A1–40  324 pg/mL;
 324 pg/mL; plasma concentration A1–42  51 pg/mL; (4) plasma
A42:A40
Model 2 Model 1 Model 2
Ref. Ref. Ref.
9)a 2.05 (1.05–4.02)a 0.99 (0.59–1.68) 1.05 (0.59–1.87)
6) 2.16 (1.14–4.09)a 0.81 (0.47–1.41) 0.95 (0.52–1.71)
5)a 1.09 (1.04–1.14)a 1.11 (1.07–1.15)a 1.09 (1.04–1.14)a
4) 1.10 (0.64–1.88) 1.21 (0.77–1.90) 1.04 (0.61–1.77)
0.99 (0.94–1.06) 1.01 (0.95–1.06)
1.19 (0.70–2.03) 1.26 (0.74–2.13)
1.21 (0.70–2.07) 1.19 (0.70–2.04)
disability (ID), and presence of at least 1 APOE 4 allele.
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shows that those with a plasma A1–42 level above the
edian but with an A1–40 level below the median are not at
increased risk of Alzheimer’s disease (p 0.16). However, the
highest risk of dementia was found in those with high concen-
trations of A1–40 in the absence or presence of high con-
centrations of A1–42 (HR, 2.39; 95% CI, 1.16–4.91; and
HR, 2.22; 95% CI, 1.16–4.24, respectively).
4. Discussion
In the present study, as far as we know the largest study
in elderly people with DS, we examined the relation be-
tween A plasma levels and the risk of developing dementia
uring follow-up. Compared with Down persons without
ementia, the prevalent and incident demented persons had
ignificantly higher plasma A1–40 concentrations at base-
ine. Plasma A1–42 concentrations and the ratio A1–42:
1–40 were lower, although not significant, in those with
dementia at baseline. As can been seen in Table 4, results
from studies examining concentrations of plasma levels of
A1–40 and A1–42 in demented and nondemented per-
sons have been controversial (Head et al., 2010; Jones et al.,
2009; Matsuoka et al., 2009; Prasher et al., 2010; Schupf et
al., 2007, 2010). Differences in assay procedures, subject
characteristics, and collection procedures among others may
have contributed to the variable findings. Even findings
within the same population (the 2 studies of Schupf et al.,
2007, 2010) are not consistent, although all these studies
used the required accurate measurement of full-length
Table 4
Relation plasma serum A levels and dementia status in different studies
Reference Assay antibody
A1–40/A1–42
Diagnosis Study
chupf et al., 2001 6E10(A1–16) Demented Cross-
R162/R165 Nondemented
Schupf et al., 2007 6E10(A1–16) Demented (prevalent) Longi
R162/R165 Demented (incident) Prospe
Nondemented
atsuoka et al.,
2009a
Elisa (A1) 82E1 Demented Cross-
1A10/1C3 Nondemented
rasher et al.,
2010
6E10(A1–16) Demented Longi
R162/R165 Nondemented
Jones et al., 2009b 6E10(A1–16) Demented Cross-
R162-R209/R226 Nondemented
Head et al., 2010c BAN50(A1–16) Demented Cross-
BA27/BC05 Nondemented
chupf et al.,
2010d
6E10(A1–16) Demented (incident) Longi
R162/R165 Nondemented Prospe
oppus (2011; this
study)d
xMAP technology Demented (prevalent) Longi
Demented (incident) Prospe
Nondemented
ey: A, amyloid beta peptide; N, number of participants; ns, not signifi
a fmol/mL (SD), adjusted for age and sex (not converted).
b SD calculated from SE and N.
c A values converted from pmol/L to pg/mL (1 pg/mL  0.284 pmol/
d Baseline levels.A1–42 and A1–40. If any trend can be deducted, the eore recent studies are more likely to show consistent
ffects. In the table, A1–42:A1–40 ratio is not given, as
this was not analyzed in all studies.
In our study, plasma A1–40 and A1–42 at baseline
ere higher in DS persons who developed dementia during
ollow-up than in persons who remained free from demen-
ia, which suggests that increased plasma concentrations of
 are associated with the development of dementia as has
been noticed by others (Matsuoka et al., 2009; Schupf et al.,
2001, 2007, 2010; Tokuda et al., 1997). In this study we
showed that high plasma concentrations of A1–40 were
associated with an increased risk of dementia, independent
of the concentration of A1–42. Analyses of the Rotterdam
tudy (van Oijen et al., 2006), the Northern Manhattan
tudy of Aging (Mayeux et al., 2003), and the Three-City
tudy (Lambert et al., 2009) also revealed that increased
evels of A1–40 were predominantly associated with in-
reased risk of developing AD. Several studies show that
ow levels of A1–42 in cerebrospinal fluid (CSF) are
strongly associated with future development of AD (Hans-
son et al., 2006, 2007). The reduction of A1–42 in CSF
eems to reflect aggregation of A1–42 in brain tissue
Hansson et al., 2010). However, it is unclear whether the
isturbed metabolism of A1–42 in the AD brain is re-
flected by changes in A in plasma. In fact, A is produced
by many different cells in the body and there seems no clear
connection between the levels of A1–42 in plasma and
SF (Hansson et al., 2010; Mehta et al., 2001). On the other
and, several longitudinal studies (Cosentino et al., 2010; Ok-
n A1–42 pg/mL
(SD)
p A1–40 pg/mL
(SD)
p
al 11 28.2 (5.9) 0.006 157.2 (35.6) ns
97 22.4 (6.1) 132.1 (44.4)
30 25.8 (7.5) 0.04 153.1 (50.7) ns
44 24.1 (5.9) 162.5 (55.1)
130 22.7 (6.1) 171.5 (54.3)
al 52 419 (660) ns 242 (321) ns
145 339 (577) 288 (384)
retrospective 44 33.2 (15.9) ns 179.6 (59.7) ns
83 33.8 (15.0) 177.8 (67.8)
al 21 27.8 (16.6) ns 125.6 (84.1) ns
39 27.1 (11.4) 121.3 (50.7)
al 52 18.6 (3.8) ns 235.5 (22.8) ns
26 16.1 (1.8) 224.2 (24.2)
61 25.4 (7.4) ns 160.7 (53.1) ns
164 26.2 (11.0) 151.9 (52.5)
62 50.0 (17.5) ns 352.3 (103.5) 0.05
79 54.0 (14.7) 362.6 (113.5)
264 51.0 (14.8) 326.4 (101.3)
, standard error; SD, standard deviation.
calculated from SE and N.design
section
tudinal
ctive
section
tudinal
section
section
tudinal
ctive
tudinal
ctive
cant; SE
L); SDreke et al., 2009) demonstrated that high initial levels of
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1993A.M.W. Coppus et al. / Neurobiology of Aging 33 (2012) 1988–1994plasma A1–42 and A1–40 and stable or decreasing
A1–42 at follow-up were associated with faster cognitive
ecline and development of dementia. Even the Tg2576 mouse
odel of AD has shown that plasma A levels decrease as
brain A levels increase (Kawarabayashi et al., 2001; Kupsch
et al., 2001). It is unclear how brain A accumulation and
cognitive decline are associated in DS. A recent report of
Netzer et al. (2010) suggests that inhibiting A production in
he Ts65Dn mouse model of DS, lowered A levels and
educed level of intellectual disability. This raises the possibil-
ty that therapy reducing the elevated levels of A may de-
crease not only the risk of AD but also improve cognition in
DS. In our study, contrary to others (Matsuoka et al., 2009), we
did not find a significant correlation between A concentra-
tions and level of intellectual disability. Further investigation
using positron emission tomography (PET) imaging or amy-
loid imaging would be very useful.
In DS, plasma analysis of A1–40 and A1–42 as
predictors of dementia will be an enormous advantage com-
pared with CSF diagnostics as a lumbar puncture is more
invasive compared with a vena puncture and often not
possible in people with DS.
Our study suggests that A1–40 and A1–42 levels are
both potential predictors of dementia in patients with DS,
independent of the risk factors of dementia in DS identified
to date (age, sex, APOE, BMI, and level of intellectual
disability). This is in line with the large epidemiological
prospective studies in the general population. However,
comparisons of studies of patients with DS also shows
major differences related to the measurements and perhaps
study design. More work needs to be carried out to fully
understand the way plasma A concentration is related to
cognitive decline and the development of AD in the general
population as well as in people with DS.
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